ZORECIMERAN

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Nucleic Acid Created by `admin` on `Wed Apr 02 08:42:30 GMT 2025` Edited by `admin` on `Wed Apr 02 08:42:30 GMT 2025`
Nucleic Acid Type	mRNA VACCINE
Sequence Origin	VIRAL
Sequence Type	COMPLETE
Record UNII	5TP24STD1S
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

ZORECIMERAN

Official Name

English

CV-07050101

Preferred Name

English

Zorecimeran [WHO-DD]

Common Name

English

MESSENGER RNA (MRNA), 5'-CAPPED, ENCODING A FULL-LENGTH CODON-OPTIMISED PRE-FUSION STABILIZED CONFORMATION VARIANT (K986P AND V987P) OF THE SARS-COV-2 (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; NC_045512.2) SPIKE (S) GLYCOPROTEIN, FLANKED BY 5' AN

Common Name

English

zorecimeran [INN]

Common Name

English

RNA (RECOMBINANT 5'-(M7G-(5'->5')-PPP-AM)-CAPPED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 PRE-FUSION SPIKE GLYCOPROTEIN (986-PROLINE,987-PROLINE)-SPECIFYING 3'-TAILED MESSENGER R9515), INNER SALT

Common Name

English

CV07050101

Code

English

CUREVAC MRNA-BASED VACCINE IMMUNOGEN CANDIDATE AGAINST COVID-19

Common Name

English

CVNCOV

Code

English

Code System Code Type Description

NCI_THESAURUS

C173851

Created by admin on Wed Apr 02 08:42:30 GMT 2025 , Edited by admin on Wed Apr 02 08:42:30 GMT 2025

PRIMARY

NCIT

CAS

2432957-15-6

Created by admin on Wed Apr 02 08:42:30 GMT 2025 , Edited by admin on Wed Apr 02 08:42:30 GMT 2025

PRIMARY

WIKIPEDIA

CureVac_COVID-19_vaccine

Created by admin on Wed Apr 02 08:42:30 GMT 2025 , Edited by admin on Wed Apr 02 08:42:30 GMT 2025

PRIMARY

INN

11868

Created by admin on Wed Apr 02 08:42:30 GMT 2025 , Edited by admin on Wed Apr 02 08:42:30 GMT 2025

PRIMARY

SMS_ID

300000021971

Created by admin on Wed Apr 02 08:42:30 GMT 2025 , Edited by admin on Wed Apr 02 08:42:30 GMT 2025

PRIMARY

FDA UNII

5TP24STD1S

Created by admin on Wed Apr 02 08:42:30 GMT 2025 , Edited by admin on Wed Apr 02 08:42:30 GMT 2025

PRIMARY

Sugar	Site Range	Site Count
D-Ribose (RNA)	1_1-1_4039	4039 / 4039

Linkage	Site Range	Site Count
Phosphate	1_1-1_4039	4039 / 4038

Related Record Type Details


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->VACCINE ANTIGEN

Amount:

Related Record Type Details


					5TP24STD1S

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
NUCLEOTIDE SUBSTITUTION	[1_1]				m2-7,3’-OGppp(m1-2’-O)Ap mRNA CAP	VNP8CZY34V